Next Meetings

Voretigene Neparvovec

Midwest CEPAC
January 25, 2018 10am-4pm CT

Courtyard Marriott at Briarcliff
4000 North Mulberry Drive
Kansas City, MO

The Midwest CEPAC will convene to deliberate on ICER's report on voretigene neparvovec.

Register or Register for the Live Webcast

March 2, 2018 10am-4pm PT

California, TBD

The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.


Hemophilia A

New England CEPAC
March 29, 2018 10am-4pm EST

Boston, MA

The New England CEPAC will convene to review the comparative clinical effectiveness and value of emicizumab for treatment of hemophilia A.


Cystic Fibrosis

Midwest CEPAC
May 17, 2018 10am-4pm CT

Midwest TBD

The Midwest CEPAC will convene to discuss treatments for cystic fibrosis.


June 22, 2018 10am - 4pm PT

CTAF will convene to review ICER's report on erenumab for prevention of migraine headaches. During this meeting, CTAF will also review a condition update on plaque psoriasis therapies.


Psoriasis Condition Update

New England CEPAC
July 12, 2018 10am - 4pm ET

TBD

The New England CEPAC will convene to review ICER's condition update on therapies for plaque psoriasis. During this meeting, the Council will also review a report on elagolix for endometriosis.


Endometriosis

New England CEPAC
July 20, 2018 10am - 4pm ET

TBD

The New England CEPAC will review ICER's report on elagolix for endometriosis.


past Meetings

Dec 2017
New England CEPAC

Tardive Dyskinesia

The New England CEPAC will convene to review ICER's evidence report assessing the clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder related to prolonged use of antipsychotic medications.


May 2017
ICER

Orphan Drug Assessment and Pricing Summit

ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.